by Bernice Lottering

作者：Bernice Lottering

Share To

共享给

Merck to acquire Curon's investigational B-cell depletion therapy, CN201, in a deal worth $1.3 billion.Merck, known as MSD outside of the United States and Canada, announced on Friday that it will acquire full global rights to Curon Biopharmaceutical’s CN201, a next-generation cell therapy drug. The deal, valued at up to $1.3 billion, positions Merck to expand its portfolio in innovative treatments, offering potential applications in treating B-cell malignancies and autoimmune diseases.Merck Secures Global Rights to CN201 with $700 Million Upfront Payment, Potential for $600 Million in MilestonesMerck, through a subsidiary, will pay $700 million upfront to secure full global rights to CN201 under the deal terms.

默克将以13亿美元的价格收购Curon的研究性B细胞耗竭疗法CN201。默克（Merck），在美国和加拿大以外被称为MSD，周五宣布将获得Curon Biopharmaceutical的CN201（一种下一代细胞治疗药物）的全部全球权利。该交易价值高达13亿美元，使默克能够扩大其在创新治疗方面的投资组合，为治疗B细胞恶性肿瘤和自身免疫性疾病提供潜在的应用。默克公司通过7亿美元的预付款获得了CN201的全球权利，在米尔斯托内斯（MilestonesMerck）拥有6亿美元的潜力。默克公司将通过一个子公司预付7亿美元，以根据交易条款获得CN201的全部全球权利。

Additionally, Curon could receive up to $600 million in milestone payments for achieving regulatory and developmental targets.CN201, an investigational bispecific antibody in the clinical stage, has potential applications in B-cell malignancies and autoimmune diseases. Currently, it is undergoing evaluation in Phase 1 and Phase 1b/2 clinical trials for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphocytic leukemia (ALL). Abnormal B cells can lead to various diseases, including autoimmune conditions and cancers.

此外，Curon可以获得高达6亿美元的里程碑付款，以实现监管和发展目标。CN201是临床阶段的一种研究性双特异性抗体，在B细胞恶性肿瘤和自身免疫性疾病中具有潜在的应用。目前，它正在复发或难治性非霍奇金淋巴瘤（NHL）和B细胞急性淋巴细胞白血病（ALL）的1期和1b/2期临床试验中进行评估。异常的B细胞可导致各种疾病，包括自身免疫性疾病和癌症。

These diseases encompass lupus, rheumatoid arthritis, multiple sclerosis, and Type 1 diabetes.In the context of CN201, preliminary data shows promising potential for patients with relapsed or refractory B-cell hematologic malignancies. In this regard, CN201 may induce significant and sustained reductions in B-cell populations, offering hope for more effective treatments. Merck and Curon Finalize $1.3 Billion Deal for CN201, With Transaction Expected to Close in Q3Dr.

这些疾病包括狼疮，类风湿性关节炎，多发性硬化症和1型糖尿病。在CN201的背景下，初步数据显示复发或难治性B细胞血液系统恶性肿瘤患者具有良好的潜力。在这方面，CN201可能会导致B细胞数量的显着和持续减少，为更有效的治疗提供了希望。默克（Merck）和柯龙（Curon）最终敲定了以13亿美元收购CN201的交易，预计交易将于第三季度完成。

Dean Li, president of Merck Research Laboratories, stated, “Ea.

默克研究实验室总裁李院长表示：“Ea。

Related Article

相关文章

Servier’s $1.8 Billion Acquisition Pays Off: FDA Approves First-In-Class Treatment for Two Types of Rare Brain CancerForeseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADCRoche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights .

施维雅18亿美元的收购取得了回报：FDA批准了两种罕见脑癌的一流治疗方法Foreseen Biotech与Ipsen达成了10.3亿美元的一流ADCRoche为AI供电的血糖监测解决方案取得CE标志，通过预测性见解加强了糖尿病护理。

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]

©www.geneonline.com保留所有权利。与我们合作：[受电子邮件保护]